"Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.

181Background: The prognosis of pts with advanced ESCC remains dismal clinically. Paclitaxel and cisplatin were used as the standard first-line regimen in ESCC for almost two decades. As a novel… Click to show full abstract

Keywords: update results; paclitaxel cisplatin; line regimen; results paclitaxel; first line

Journal Title: Journal of Clinical Oncology
Year Published: 2021

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
0

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended